Explore

Rapid Read Rapid Read
Sonire Therapeutics Launches First U.S. Clinical Trial for Pancreatic Cancer Treatment

Sonire Therapeutics Launches First U.S. Clinical Trial for Pancreatic Cancer Treatment

Sonire Therapeutics, a clinical-stage medical device company, has initiated its first U.S. clinical trial, SUNRISE-II, to evaluate its High-Intensity Focused Ultrasound (HIFU) therapy system for treating pancreatic cancer. This trial aims to assess the safety and feasibility of the ultrasound-guided HIFU system, marking a significant milestone in the company's U.S. clinical and regulatory strategy. The trial builds on previous development experience in Japan and represents an important step toward advancing treatment options for pancreatic cancer, a leading cause of cancer-related deaths in the U.S. The HIFU system offers a minimally invasive, anesthesia-free treatment approach, potentially reducing procedural burdens and expanding access to treatment in outpatient settings.
Rapid Read Rapid Read
Samuelis Donate $50 Million to Israeli Cancer Research at Beilinson Medical Center

Samuelis Donate $50 Million to Israeli Cancer Research at Beilinson Medical Center

Henry and Susan Samueli have made a significant philanthropic contribution by donating $50 million to Beilinson Medical Center in central Israel. This donation is aimed at advancing cancer treatment and research at the facility. The Samuelis' gift is part of a broader trend in philanthropy where donors are increasingly participating in collaborative efforts rather than establishing large, independent foundations. This approach allows for pooling resources and leveraging expertise to address global challenges more effectively. The donation is expected to enhance the medical center's capabilities in providing cutting-edge cancer care and conducting vital research.
Trendline Trendline
Novocure Reports 12% Revenue Growth in Q1 2026 Driven by Global Expansion

Novocure Reports 12% Revenue Growth in Q1 2026 Driven by Global Expansion

Novocure Reports 12% Revenue Growth in Q1 2026 Driven by Global Expansion
Rapid Read Rapid Read
Innovative Chewing Gum Aims to Combat Cancer-Related Microbes

Innovative Chewing Gum Aims to Combat Cancer-Related Microbes

Researchers at the University of Pennsylvania have developed a chewing gum that may help reduce cancer-associated oral microbes, particularly in patients with head and neck squamous cell carcinoma (HNSCC). The gum, made with proteins from lablab beans, has shown promise in reducing levels of harmful microbes like HPV, Porphyromonas gingivalis, and Fusobacterium nucleatum. The gum's mechanism involves binding viruses and bacteria, potentially offering a complementary treatment to existing therapies. Trials for this antiviral gum are set to begin in the U.S., following evaluations in London.
Reuters Reuters
US FDA authorizes early access to Revolution's pancreatic cancer pill

US FDA authorizes early access to Revolution's pancreatic cancer pill

May 1 (Reuters) - The U.S. Food and Drug Administration has authorized the granting of early access before regulatory approval to Revolution Medicines’ pill for patients with previously treated pancreatic cancer, the company said on Friday.
Trendline Trendline
Novocure Reports Strong Q1 2026 Financial Results with Growth in Optune Gio Therapy

Novocure Reports Strong Q1 2026 Financial Results with Growth in Optune Gio Therapy

Novocure Reports Strong Q1 2026 Financial Results with Growth in Optune Gio Therapy
Trendline Trendline
Genprex Secures Israeli Patent for Cancer Gene Therapy Combination

Genprex Secures Israeli Patent for Cancer Gene Therapy Combination

Genprex Secures Israeli Patent for Cancer Gene Therapy Combination
Reuters Reuters
US FDA approves Pfizer, Arvinas' breast cancer drug

US FDA approves Pfizer, Arvinas' breast cancer drug

By Padmanabhan Ananthan May 1 (Reuters) - The U.S. Food and Drug Administration on Friday approved Pfizer and Arvinas' breast cancer drug for patients with an advanced form of the disease whose tumors carry a specific genetic mutation.
Rapid Read Rapid Read
AI Model REDMOD Shows Promise in Early Detection of Pancreatic Cancer

AI Model REDMOD Shows Promise in Early Detection of Pancreatic Cancer

Researchers at the Mayo Clinic and University of Texas MD Anderson Cancer Center have developed an AI model named REDMOD, which has shown significant promise in detecting pancreatic cancer much earlier than current methods. The AI was tested on CT scans and successfully identified the most common form of pancreatic cancer approximately 16 months before diagnosis in nearly 75% of cases. This is nearly double the detection rate of specialists without AI assistance. REDMOD works by identifying subtle radiomic patterns in tissue that are often missed by the human eye. The model was trained on 969 CT scans and tested on additional scans, demonstrating a high level of accuracy and consistency across different clinical settings.
Trendline Trendline
Innovative Chewing Gum Shows Promise in Reducing Cancer-Associated Microbes

Innovative Chewing Gum Shows Promise in Reducing Cancer-Associated Microbes

Innovative Chewing Gum Shows Promise in Reducing Cancer-Associated Microbes
Trendline Trendline
enVVeno Medical Secures FDA IDE Approval for Pivotal Study on Non-Surgical Venous Valve

enVVeno Medical Secures FDA IDE Approval for Pivotal Study on Non-Surgical Venous Valve

enVVeno Medical Secures FDA IDE Approval for Pivotal Study on Non-Surgical Venous Valve
Rapid Read Rapid Read
Capitan Orthopedics Receives FDA Breakthrough Device Designation for SupraSpacer Implant

Capitan Orthopedics Receives FDA Breakthrough Device Designation for SupraSpacer Implant

Capitan Orthopedics, Inc. has announced that its SupraSpacer™ implant has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA). This implant is designed to address irreparable rotator cuff tears, a condition affecting over 2 million people annually in the U.S., with more than 700,000 undergoing surgery each year. The SupraSpacer™ offers a biomechanical solution that aims to reduce pain and improve patient function by maintaining joint alignment and allowing a full range of motion. The implant is particularly beneficial for patients under 60, for whom traditional soft tissue procedures or reverse shoulder replacements are not ideal. Capitan Orthopedics, backed by Genesis Innovation Group, aims to fill a significant gap in the care continuum for these patients.